Showing 2421-2430 of 2527 results for "".
- Opternative Changes Names to Visibly To Better Reflect Eye Care Industry Partnershipshttps://modernod.com/news/opternative-changes-names-to-visibly-to-better-reflect-eye-care-industry-partnerships/2479622/Opternative announced that it has changed its name Visibly to better represent the eye care industry, according to a company news release. “We understand that our previous company name, Opternative, carried a negative connotation in the eye care industry and positioned the brand as a
- 4D Molecular Therapeutics Announces Collaboration to Advance Gene Therapies for Retinal Diseases with Oregon Health & Sciencehttps://modernod.com/news/4d-molecular-therapeutics-announces-collaboration-to-advance-gene-therapies-for-retinal-diseases-with-oregon-health-science/2476157/4D Molecular Therapeutics (4DMT) announced a research and development collaboration with the Casey Eye Institute and the Oregon National Primate Research Center at Oregon Health & Science University (OHSU). The collaboration will combine the complementary expertise of 4D Molecular Therapeutic
- ProQR Announces Clearance of IND to Start Clinical Trial of QR-421a in Usher Syndrome Type 2 Patientshttps://modernod.com/news/proqr-announces-clearance-of-ind-to-start-clinical-trial-of-qr-421a-in-usher-syndrome-type-2-patients/2476165/ProQR Therapeutics announced that the FDA has cleared the investigational new drug (IND) application for QR-421a. QR-421a is a first-in-class investigational RNA-based oligonucleotide designed to address the underlying cause of the vision loss associated with Usher syndrome type 2 and non-syndrom
- Alcon Launches Alcon Retina Fellows Institute to Support Future Leaders of Ophthalmologyhttps://modernod.com/news/alcon-launches-alcon-retina-fellows-institute-to-support-future-leaders-of-ophthalmology/2479630/Alcon announced it is expanding its support of eye care professionals through the launch of a one-of-a-kind training opportunity, the Alcon Retina Fellows Institute. The unique educational offering supports retina fellows during a weekend-long training at the Alcon Experience Center in Fort Worth
- Envision Conference to Split in Two in 2019https://modernod.com/news/envision-conference-to-split-in-two-in-2019/2479634/For the first time since its inception in 2006, Envision Conference will be split into two events for the upcoming year: Envision Conference East, March 22-23, 2019 at the University of Alabama at Birmingham in Birmingham, Alabama; and Envision Conference West, October 5-6, 2019 at the College of
- Research Exposes Disparity Between ECPs’ Personal Wearing Habits and Prescribing Habits for Healthiest Contact Lens Materialhttps://modernod.com/news/research-exposes-disparity-between-ecps-personal-wearing-habits-and-prescribing-habits-for-healthiest-contact-lens-material/2479687/New data from CooperVision shows a disparity between what eye care professionals (ECPs) in the United States choose for their personal contact lens wear versus what they prescribe for patients. Among 183 surveyed U.S. optometrists who wear 1-day contact lenses, 72% prefer a silicone hydrogel prod
- Eye Health America Completes Acquisition of Tampa Bay-Based Updegraff Laser Visionhttps://modernod.com/news/eye-health-america-completes-acquisition-of-tampa-bay-based-updegraff-laser-vision/2479695/Eye Health America (EHA) announced its sixth acquisition of the year, adding Updegraff Laser Vision to its roster of prominent eye care member practices in the Southeast United States. Terms of the deal were not disclosed. The acquisition of the Tampa Bay-based practice continues to
- Pressure Intensifies to Lower Drug Priceshttps://modernod.com/news/pressure-intensifies-to-lower-drug-prices/2479696/The price of ophthalmic drugs varies widely in the United States, and this can adversely affect patient care, data from a new study show, according to a report in Medscape. “Our patients are the ones who are suffering because
- Oxurion and Beta Therapeutics To Develop New Heparanase Inhibitors for Treatment of dry AMDhttps://modernod.com/news/oxurion-and-beta-therapeutics-to-develop-new-heparanase-inhibitors-for-treatment-of-dry-amd/2479697/Oxurion announced that it entered into a strategic research collaboration with Beta Therapeutics (Canberra, Australia) to develop new heparanase inhibitors for the treatment of retinal disorders with large unmet medical needs such as dry age-related macular degeneration. Under the terms of
- Prevent Blindness Elects Three New Members to National Board of Directorshttps://modernod.com/news/prevent-blindness-elects-three-new-members-to-national-board-of-directors-2/2479700/Prevent Blindness has announced that Paul Delatore, Global Head, Market Access at Alcon; Jim McGrann, Chairman & CEO of Healthy Eyes Advantage; and Rajeev S. Ramchandran, MD, Associate Professor of Ophthalmology in the University of Rochester Medical School’s Department of Ophthalmology, have